Background: Environmental challenges during development affect the fetal epigenome, but the period(s) vulnerable to epigenetic dysregulation is(are) not clear. By employing a soy phytoestrogen, genistein, that is known to alter the epigenetic states of the A vy allele during embryogenesis, we have explored the sensitive period for epigenetic regulation. The post-implantation period, when de novo DNA methylation actively proceeds, is amenable to in vitro analysis using a mouse embryonic stem (ES) cell differentiation system.
Introduction
In mammals, the intrauterine environment affects the fetal epigenome. For example, maternal dietary genistein increases the level of DNA methylation at the cryptic promoter derived from intracisternal A-particle insertion in the agouti gene (the viable yellow allele of agouti is denoted A vy ) [1] . This genistein-induced hypermethylation of A vy occurs to a similar extent in tissues from all three germ layers (brain, liver, and kidney) and persists into adulthood. Because A vy undergoes epigenetic reprogramming after fertilization [2] , alteration of DNA methylation patterns by genistein would probably occur within the developmental window after fertilization but before germ layer differentiation [3] .
During early embryonic development, approximately at implantation, the DNA methylation patterns of individual promoters dynamically change. For example, the methylation of specific sites in Apoa1 is erased after fertilization; after implantation, methylation is restored by the gastrulation stage [4] . Recent genome-wide analysis of promoter DNA methylation in the early embryo has confirmed that de novo methylation occurs during implantation in 476/691 promoters that are methylated in the E9.5 embryo [5] .
Of importance, DNA methylation patterns established around implantation can be modified by further methylation or demethylation during subsequent stages of organogenesis [5] . However, the influence of environment on DNA methylation dynamics of intrinsic promoters is still unknown.
To clarify how environmental factors affect DNA methylation dynamics, especially during the post-implantation period, we characterized the alterations in DNA methylation patterns induced by genistein in an embryonic stem (ES) cell differentiation system. We developed a novel DNA methylation assay, MspI fragmentbased DNA methylation typing (MFMT), for use in combination with a mouse promoter microarray to identify genistein-mediated differentially methylated regions (DMRs). Of the 149 DMRs identified, 54 regions were more methylated and 95 regions were less methylated in genistein-treated cells than in control cells. Among these DMRs, 74 regions were located proximal to the transcriptional start site (TSS) of adjacent gene(s). The genisteinmediated hypomethylation of the Ucp1 and Sytl1 promoters was further analyzed for the effects of genistein on methylation dynamics. Bisulfite sequencing confirmed the decrease in methylation levels of both promoters on day 10 . Of interest, the methylation levels of the Ucp1 and Sytl1 promoters peaked on day 4, and peak levels were equivalent in genistein-treated and untreated cells. Thus, once de novo DNA methylation of these promoters was complete, genistein appeared to accelerate the subsequent decline in methylation levels. Our results suggest that genistein influences DNA methylation established around the post-implantation period, which may partly explain the vulnerability of the embryonic epigenome to intrauterine environmental changes.
Materials and Methods

ES cell culture and differentiation
ES cells were maintained in Dulbecco's Modified Eagle Medium (Sigma, St. Louis, MO) with 15% fetal calf serum (Millipore, Billerica, MA), 10 3 U ml 21 leukemia inhibitory factor, 0.1 mM MEM non-essential amino acids (Sigma), 16 nucleosides mix, 2 mM L-glutamine, penicillin/streptomycin, and 40 mM 2-mercaptoethanol (Sigma). ES cell lines CCE (strain 129/Sv) and E14Tg2a (strain 129/Ola), gifts of Dr. A. Miyajima (University of Tokyo), are feeder-independent. For ES cell differentiation, embryoid body (EB) formation was induced by hanging-drop culture without leukemia inhibitory factor for 2 days, followed by 2 days of suspension culture and 6 days of culture on gelatinized dishes. During differentiation, ES cells were treated with the indicated concentrations of genistein (0, 1, 5, or 10 mM) dissolved in dimethyl sulfoxide (DMSO); the medium was replaced every other day. The final DMSO concentration in all the samples was 0.01% (v/v). From differentiation day 8 to day 12, the proportion of EBs with contracting myocardiocytes was evaluated. Concentrations of up to 5 mM genistein did not impair cardiac differentiation ( Figure S1 ).
Real-time PCR analysis
Esr1, Esr2, Pou5f1, T, Fgf5, Wnt3a, Pdgfra, Tbx5, Gata4, and Gata6 mRNA levels were measured by real-time RT-PCR in a LightCycler 480 (Roche Applied Science, Mannheim, Germany). Total RNA was extracted from ES cells (day 0, day 4 of control, day 4 of genistein-treated, day 10 of control, and day 10 of genistein-treated) using the RNeasy mini kit (QIAGEN, Hilden, Germany). After treatment with DNase I (Invitrogen, Carlsbad, CA), cDNA was synthesized from 1 mg RNA per reaction with 200 U Superscript III, 2.5 mM oligo (dT) 20 , 0.5 mM dNTP, 5 mM MgCl 2 , and 10 mM DTT in reaction buffer (Invitrogen) at 50uC for 50 min. All reactions were run together with RT minus controls. After termination of cDNA synthesis at 85uC for 5 min, the reaction mixture was further incubated with RNase H at 37uC for 20 min. Real-time PCR was performed using the LightCycler 480 Probe Master kit (Roche Applied Science) and the specific primers and the corresponding Universal Probe Library probe (Roche Applied Science) according to the manufacturer's instructions. The identification numbers of Universal Probe Library probes and primer sequences are listed in Table S1 . Normalized gene expression values, calibrated with the value on day 0, were obtained with LightCycler Relative Quantification software (ver 1.5, Roche Applied Science) using Actb as a reference gene ( Figures S2 and S8 ). MspI fragment-based DNA methylation typing (MFMT): assay and analysis Genomic DNA was extracted from control cells (DMSO only) and genistein-treated cells at day 10 of CCE differentiation using the QIAamp DNA Mini kit (QIAGEN). A total of 200 ng of each DNA sample was digested to completion for 3 h with 10 U MspI, and the digested DNA was purified with the MinElute Reaction Clean-up kit (QIAGEN). Two complementary oligonucleotides (59-AGCACTCTCCAGCCTCTCACCGAC-39 and 59-CGGT-CGGTGAGAGGCTGG-39) were annealed and ligated to the MspI fragments, and their 39 ends were extended with Platinum Taq DNA polymerase (Invitrogen, Carlsbad, CA) at 72uC for 15 min. The reaction mixture was then divided into three aliquots and subjected to enzymatic digestion for 4 h. One aliquot was treated with 10 U MspI, another with 10 U HpaII, and the third aliquot with 10 U McrBC ( Figure S3 ). Ligation-mediated PCR (LM-PCR) was carried out for each product with the FastStart High Fidelity PCR System (Roche, Mannheim, Germany) in buffer containing 1.8 mM MgCl 2 , 2% DMSO, and the specific primer 59 -GCCTCTCACCGACCGG-39. Amplification conditions consisted of a hot start at 95uC for 2 min, followed by 26 cycles of 95uC for 20 s, 72.9uC for 20 s, and 73uC for 30 s; 18 cycles of 95uC for 20 s, 72.3uC for 20 s, and 73uC for 10 s; 8 cycles of 95uC for 20 s, 71.0uC for 20 s, and 73uC for 30 s; and finally a hold at 72uC for 5 min. The quality of the LM-PCR reaction was tested with the Agilent 2100 bioanalyzer (Santa Clara, CA). PCR products were purified with a MinElute Reaction Clean-up kit, and were labeled with Alexa 555 or 647 using the BioPrime Plus Array CGH Genomic Labeling System (Invitrogen) in accordance with the manufacturer's instructions, with the exception of a use of 100 U Klenow fragment per labeling reaction. The labeled PCR products were mixed and then hybridized to the NimbleGen (Madison, WI) mouse 385K CpG Island Plus Promoter Array (cat# 00893), according to the manufacturer's protocol. Hybridized arrays were scanned with a NimbleGen MS200 Scanner, and the images were analyzed with NimbleScan software (ver 2.6).
The NimbleGen mouse 385K promoter array contains 373,638 probes in total on average ,1.3 kb of upstream sequence and ,0.5 kb of downstream sequence from the TSS, covering 15,963 promoters/CpG islands. Each probe is 50-70 nucleotides in length, with roughly 18 probes per region with 100-bp spacing. We selected a subset of probes for our analysis ( Figure S3 ). First, we excluded the probes that contain the MspI recognition sequence (CCGG). Next, because the LM-PCR products were generated mainly in the 100-1000 bp size range, we focused on probes enclosed by two MspI sites with an interval length between 100 and 1000 bp ( Figure S3 ). Our selection criteria led to the retention of 127,857 (34.2% of the total NimbleGen probes) for further analysis.
If the CpG at the end of the MspI-digested fragment is methylated, the adaptor-ligated product remains resistant to HpaII digestion, so that the LM-PCR product (the HpaII-resistant product) can be fully generated ( Figure S3 To evaluate the methylation detection performance of the MFMT assay, we calculated the mean log 2 (HpaII r /McrBC r ) values for the MspI fragments in several methylation-control promoters. Because there was no precise information about the promoter DNA methylation levels in day-10 differentiated ES cells, we searched the possible candidates for universally (in somatic cells) methylated or unmethylated promoter regions by using previously published data [6] . For selection of the methylated regions, we considered three criteria as follows: (1) mean methylation levels assayed by RRBS (reduced representation bisulfite sequencing) were high (.0.30) in ES, NPCs (neural precursor cells), astrocytes, whole brain, CD4+ T cells, CD8+ T cells, B cells, MEFs (mouse embryonic fibroblasts), tail-tip, liver, spleen, and lung ( [6] ); (2) a germ-line-specific promoter was present; and (3) the promoter region contained a pair of adjoining MspI sites with an interval that was long enough to contain more than two consecutive probes of the microarray and short enough for LM-PCR to achieve the MFMT assay. Eventually, seven regions of Dazl, Sycp1, Tuba3a, Spo11, Hormad1, AU022751, and Sycp2 were selected as ''methylation positive controls.'' On the other hand, for the unmethylated regions, we considered three criteria as follows: (1) mean methylation levels assayed by RRBS were low (,0.20) in all the samples analyzed by Meissner et al. [6] ; (2) there was a ubiquitously expressed gene promoter; and (3) the promoter or CpG island region contained a pair of adjoining MspI sites with an interval length that was adequate for the MFMT assay. Although over 2000 gene promoters met two criteria, such as (1) and (2), less than half met a third criterion because of socalled HpaII Tiny Fragments (HTFs) ( [7] ). Among these, we selected 46 regions that are highly transcribed in ES cells as ''methylation negative controls.'' Figure S4 shows the scatter plot of the mean log 2 (HpaII r /McrBC r ) values of untreated and genistein-treated samples for these methylation control regions. The blue dots represent methylation-positive whereas the red dots indicate methylation-negative controls. Figure S5 shows the detailed information about the four representatives of these control regions (Dazl, Spo11, Dhfr, and Psmd1). Thus, the mean log 2 ) probe values from the control and 5 mM genistein-treated samples. All the statistical computation and graphics were performed using the R Statistical Package (http:// www.r-project.org/). Gene ontology analysis was conducted using the Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7 [8] .
Bisulfite sequencing
One microgram of genomic DNA from ES cells and tissues was bisulfite converted with an EpiTect Bisulfite Kit (QIAGEN) using a standard protocol. Bisulfite conversion of embryonic genomic DNA was performed with the EZ DNA Methylation-Direct Kit (Zymo Research, Orange, CA). Bisulfite sequencing primers are Position: GEN-mediated DMRs were identified by MspI fragment-based DNA methylation typing; these DMRs contain more than two consecutive probes with log 2 (HpaII r /McrBC r ) values unidirectionally different between the control and GEN-treated samples; the difference is greater than mean 6 3SD ( Figure S6 ). Positions of each DMR in the mouse genome assembly, February 2006, NCBI36/mm8, are shown. Gene(s): the names of the gene(s) adjacent to the DMR are given. In some cases, a DMR contained two distinct, bi-directional promoters. Control and GEN: the mean and standard deviation of the log 2 (HpaII r /McrBC r ) values for all probes within the DMR. Data were sorted from high to low for the Control log 2 (HpaII r /McrBC r ) data. DM/T: the ratio of the number of differentially methylated (DM) probes (the difference is greater than mean 6 3SD) to the total (T) number of probes within a DMR. Class: promoter classification based on the CpG density. High CpG-density promoters (HCPs) contain at least one 500-bp region with GC content .0.55 and have a ratio of observed to expected CpGs .0.6. Low CpG-density promoters (LCPs) lack the 500-bp GC-rich interval and the ratio of observed to expected CpGs is .0.4. Intermediate CpG-density promoters (ICPs) have characteristics between HCPs and LCPs. Ref.
: the methylation levels of the various types of tissues of the corresponding region in human genome. Methylation levels of Methylated (M), Intermediately methylated (I), and Unmethylated (U) derive from the Ensembl genome-wide DNA methylation resource (E-TABM-445). ND denotes a lack of available information about the methylation level of the human counterpart. *This DMR integrated two proximate probes that were similarly hypomethylated following GEN treatment; one probe resided in the MspI interval of chr14:101869393-101869526, and the other was in chr14:101869523-101869657. doi:10.1371/journal.pone.0019278.t002
shown in Table S2 . PCR products were cloned into the pT7Blue T-vector (Novagen, Madison,WI) and transformed into Escherichia coli. Plasmid DNA from positive colonies was purified and sequenced at the Tokyo Medical and Dental University Genome Analysis Facility (Tokyo, Japan). Sequence and statistical analyses were performed with the QUantification tool for Methylation Analysis; http://quma.cdb.riken.jp/top/quma_main_j.html [9] . The statistical significance of the difference between two bisulfite 
Mouse embryos and adult tissues
All animal work was conducted in accordance with our institution's ethical guidelines for animal experiments. The protocols for animal handling and treatment were reviewed and approved (approval ID: S-22038) by the Animal Care and Use Committee at Tokyo Medical University (Tokyo, Japan). Oocytes were collected from the oviducts of C57BL/6J unmated female mice that were treated for superovulation by intraperitoneal injection of 5 U of pregnant mare serum gonadotropin followed 48 hr later by 5 U human chorionic gonadotropin. Twenty hours after the second injection, oocytes were collected and fertilized in vitro with C57BL/6J sperm. Zygotes were cultured in drops containing M16 medium covered with mineral oil. To obtain E6.75 and E10 embryos, two-cell embryos were transferred into day-0.5 pseudo-pregnant ICR female mice the next day. For the E6.75 stage, seven embryos were collected and genomic DNA was isolated. For the E10 stage, genomic DNA samples were isolated separately from two independent embryos. Genomic DNA was isolated from adult mouse liver and lung with the QIAamp DNA Mini Kit (QIAGEN).
Results
Identification of genistein-mediated DMRs
By day 10 of differentiation, ES cells give rise to a variety of cells, including contracting cardiomyocytes. Exposure to 5 mM genistein did not affect cardiomyocyte differentiation of ES cells, indicating that treatment is not toxic ( Figure S1 ). The analysis of differentiation marker expression also indicated that 5 mM genistein did not impair overall ES cell differentiation ( Figure  S2 ). The global DNA methylation patterns in differentiated ES cells with or without genistein treatment were analyzed with the MFMT assay, which involves using either HpaII or McrBC to dissect the methylation status of the end or interior CpGs for every MspI fragment, respectively ( Figure S3 ). Methylation levels are reflected in the log 2 (HpaII resistant(r) /McrBC resistant(r) ) value for each microarray probe (see Materials and Methods for details).
Genistein-mediated global changes in methylation levels were assessed by the difference of the log 2 (Figures S4 and S5) . Thus, although genistein treatment did not alter the DNA methylation levels in most regions detected by this assay, a subset of loci showed significant differences in their methylation levels.
Next, the difference in the log 2 (HpaII r /McrBC r ) values for each probe was calculated between the control and genisteintreatment datasets (mean = 0.048, standard deviation = 0.379; Figure S6 ). We selected probes with log 2 (HpaII r /McrBC r ) differences larger than the mean consecutive difference; of these probes, 1330 probes indicated regions hypomethylated following genistein treatment (values above the upper limits of the mean consecutive difference; mean plus three standard deviations), whereas 952 probes reflected hypermethylation of regions following genistein treatment (values below the lower limits of the mean consecutive distance; mean minus three standard deviations). However, the most pertinent methylation differences are represented by the same directional log 2 (HpaII r /McrBC r ) changes across multiple probes that are in close proximity to one another on the genome; thus, we identified loci with more than two differentially methylated probes. Out of 1330 hypomethylation and 952 hypermethylation probes, 223 (16.7%) and 117 (12.3%) probes, respectively, comprised sets of consecutive probes within the same MspI fragment or adjoining MspI fragments. Therefore, we regarded those MspI fragments as genisteinmediated DMRs ( Figure S7 ).
We identified a total of 149 DMRs, of which 54 regions were more methylated and 95 regions were less methylated in genisteintreated cells than in control cells (Table 1) . Approximately half of these DMRs (48.3%) were located in promoters, while the other half (50.3%) occurred in gene-body regions. Fifty-one DMRs were located in proximal promoter regions (less than 200 bp from TSS), nine of which contained bi-directional promoters. We performed gene ontology analysis using the DAVID Functional Annotation tool for all 155 genes contained in DMRs, excluding one noncoding RNA and two non-genic regions. Thirty-eight genes (24.5%) were related to ''gene expression'' in the Gene Ontology category (p,2.3610 24 ), while 25 (16.1%) and 7 genes (4.5%) were related to ''embryo'' (p,0.016) and ''fetal brain'' (p,0.036), respectively, in the Tissue_Expression category (Table S3 ). The indicated p-values correspond to modified Fisher's exact p-values for gene-enrichment analysis (EASE score). No further specific category was enriched in the genistein-mediated DMRs.
Seventy-four DMRs (mean length ,290 bp) were located in proximal promoters and the first exon of genes (Tables 2-5 ). In general, the sequences of the regions close to TSSs are relatively conserved between human and mouse [10] . Furthermore, bisulfite sequencing across matched tissues from human and mouse revealed strongly conserved patterns of DNA methylation in CpG island regions of SHANK3 promoter regions (including alternative promoters) [11] . Therefore, for 64 DMRs CpG methylation data from the corresponding human regions were acquired from the available public resources [11, 12] . Most DMRs contained High CpG-density promoters (HCPs), and the somatic methylation levels of their human counterparts were ''unmethylated.'' Additionally, 10 intermediate CpG-density promoters (ICPs) and 7 low CpG-density promoters (LCPs) were found in genistein-mediated DMRs, with the somatic methylation levels of the human counterparts varying from ''unmethylated'' to ''methylated'', including four counterparts (Ucp1, Sytl1, Hspb3, and Ripk3) with ''intermediate'' methylation levels. Because ICPs and LCPs are thought to be primary targets for DNA methylation [5] , these four promoters could possibly be DNA methylated as well in mouse cells. This possibility prompted us to address the question of how genistein influences DNA methylation levels of ICP and LCP promoters in the early embryonic stages.
The Ucp1 promoter is differentially methylated upon genistein treatment
From the genistein-mediated DMRs, we selected the Ucp1 and Sytl1 promoter regions as representative of the ICP and LCP promoters, respectively, for further analysis. First, we confirmed the MFMT results on the Ucp1 gene by bisulfite sequencing (Figure 2) . We identified the MspI fragment at chr8: 86180062-86180386 (NCBI36/mm8; from 2404 to 283 relative to the TSS) as a genistein-mediated DMR because the mean log 2 Figure 2A, B) . Bisulfite sequencing analysis from two independent experiments revealed that methylation levels in the Ucp1 region (2285 to +180) were significantly lower following genistein treatment ( Figure 2C ; Fisher's exact test, p,0.0192); the region analyzed by bisulfite sequencing overlaps with the DMR identified by the MFMT assay. Although genistein did not affect the CpG methylation level at the 283 MspI site, the methylation level of the McrBC site at 2126 changed considerably ( Figure 2C ). Therefore, bisulfite sequencing was consistent with the MFMT assay, indicating that genistein treatment decreases the methylation levels of the Ucp1 promoter. This decrease was also confirmed using another ES cell line, E14Tg2a ( Figure 2D ).
De novo methylation of the Ucp1 promoter
Next, we asked whether the Ucp1 promoter region underwent de novo DNA methylation during ES cell differentiation. Methylation levels were analyzed by bisulfite sequencing. The Ucp1 promoter region was unmethylated before differentiation (day 0); the methylation levels increased until day 4 and decreased thereafter, and there was no significant difference in the methylation level of the Ucp1 promoter between control and genistein-treated cells on day 4 (Fisher's exact test, p,0.43) ( Figure 3A) . While the developmental stage of day 4 ES cell differentiation corresponds to the gastrula stage of the early embryo [13] , the day 10 ES cell differentiation stage possibly corresponds to E8-10 embryos, which are initiating early organogenesis. We observed that the methylation levels of the Ucp1 promoter in early normal embryos were much higher at E6.75 (gastrula) than at E10 (early organogenesis) ( Figure 3B ), suggesting that the methylation level of the Ucp1 promoter is transiently elevated by the time of the gastrulation stage, but is subsequently demethylated in the course of further development.
The Sytl1 promoter region is differentially methylated following genistein treatment
We also used bisulfite sequencing to investigate the methylation states of another genistein-mediated DMR, the Sytl1 promoter ( Figure 4) Figures 4A, B) . Bisulfite sequencing of the region from 2221 to +220 (7 CpGs; Figure 4C ) in day 0, day 4, and day 10 CCE ES differentiation samples revealed that the Sytl1 promoter was moderately methylated on day 0. The methylation level increased until day 4 in a manner that genistein treatment did not affect. The methylation level had decreased by day 10, but of note, the methylation decrease occurred at different positions in the control (+66) and genisteintreated (223) cells. The overall methylation level following genistein treatment was lower than in control cells on day 10. The CpG methylation level at the HpaII site at 281 was also slightly lower in genistein-treated cells than in control cells, suggesting that the MFMT assay could detect the slight difference in methylation levels of this HpaII site. Thus, genistein treatment influenced the methylation levels of the Ucp1 and Sytl1 promoters in a similar fashion.
Discussion
Epidemiological and animal studies have demonstrated that nutrition and other environmental stimuli influence prenatal developmental pathways, thereby inducing permanent changes in metabolism and chronic disease susceptibility. Epigenetic alteration caused by the intrauterine environment may partly explain trait diversity, including disease phenotypes. Nevertheless, little is known about the causal relationship between the intrauterine environment and epigenetic dysregulation, probably because somatic methylome establishment consists of multiple developmental steps. Considerable attention has been paid to alterations in the fetal epigenome induced by nutritional stimuli in utero, as clearly demonstrated by changes in the methylation levels of the A vy allele resulting from maternal intake of genistein [1] , bisphenol A [14] , or methyl donors [15, 16] . These somatic epigenetic changes are thought to have occurred before germ layer differentiation in the early embryo [3] . Therefore, it is important to elucidate the effects of environmental modification on the fetal epigenome, particularly in this early developmental stage.
Because the in vitro ES cell differentiation by means of embryoid body formation is widely used for analysis of early embryogenesis around the post-implantation period, we compared the changes in DNA methylation states of the differentiated ES cell cultures between control and genistein-supplemented conditions. We added genistein to ES cell cultures at a physiological concentration of 5 mM without impairing the overall differentiation for at least 10 days (Figures S1 and S2 ). As expected, genistein treatment did not affect global DNA methylation patterns (Figure 1 ), but we could identify 74 regions proximal to TSSs that were differentially methylated following genistein treatment (Tables 2-5 ). We performed gene ontology analysis using the DAVID Functional Figure 3 . Developmental dynamics of Ucp1 methylation and the influence of genistein (GEN). Methylation levels were analyzed by bisulfite sequencing. The black inlay is the mean methylation level of each CpG, and the left panel contains the number of sequenced clones and the mean methylation level of all CpGs. A: The methylation levels of the Ucp1 promoter dynamically changed during embryonic stem (ES) cell differentiation. In undifferentiated (day 0) ES cells, most CpGs in the Ucp1 promoter were unmethylated. Although the methylation levels increased by day 4, there was no significant difference between methylation levels in control (24.7%) and GEN-treated samples (27.3%; p,0.43, Fisher's exact test). On day 10, the methylation level of the Ucp1 promoter in GEN-treated cells (14.7%) was significantly lower than in control cells (20.7%; p,0.0192), and the overall methylation levels were decreased on day 10 compared with day 4. B: The methylation levels of the Ucp1 promoter in early embryos are shown. As the embryo developed, the methylation level declined between E6.75 and E10. doi:10.1371/journal.pone.0019278.g003
Annotation tool for DMRs; however, a specific category was not significantly enriched in the genistein-mediated DMRs. This result may be attributable to an effect of genistein on a general or unspecified pathway in the early embryonic stage rather than on differentiated functions.
We also investigated in detail the methylation states of the Ucp1 and Sytl1 promoters (Figures 2-3 and 4, respectively) . The initiation time for de novo methylation varies from one promoter to another, and some promoter methylation is erased during somatic development [5] . Similarly, we found that the methylation levels of the Ucp1 and Sytl1 promoters dynamically change within a short period of early embryonic development. De novo methylation and subsequent demethylation starts early for these promoters. Methylation of the Ucp1 promoter substantially decreased during the E6. 75-10 stage of the embryo. Similarly, the Ucp1 and Sytl1 promoters underwent de novo DNA methylation until day 4 of ES differentiation, and were subsequently demethylated by day 10 ( Figures 3 and 4) . It was interesting that genistein treatment did not affect de novo methylation, as peak methylation levels did not differ between control and genistein samples; in contrast, genistein treatment changed methylation levels in the later stage (Figures 3  and 4) . Because early tissue precursor cells appear after gastrulation, it is tempting to speculate that genistein changes the methylation prototype of those precursor cells. The increase in the expression level of ERa (Esr1) could partly explain the genistein sensitivity on day 10 observed here ( Figure S8 ), but it remains to be further elucidated whether nuclear receptors such as ERa and/or ERb are involved in alteration of DNA methylation levels in genistein-mediated DMRs.
Ucp1 functions as a mitochondrial uncoupling protein in brown adipose tissue; the CpG methylation level in the Ucp1 enhancer (especially at the CRE3 site) is remarkably low in brown adipose tissue cells [17] . On the other hand, promoter methylation is known to be important for Ucp1 silencing in white adipose tissue [17, 18] . In this study, upon ES differentiation, the Ucp1 enhancer gained methylation, and genistein treatment rather amplified this increase in methylation levels ( Figure S9) . Thus, the genisteinmediated decrease in methylation levels was restricted only to the promoter region. Mitochondrial biosynthesis is activated upon cell-fate commitment during the course of ES cell differentiation [19] . In addition, genistein and other isoflavones promote mitochondrial biogenesis [20] . These issues could be relevant to the regulation of Ucp1 methylation states and warrant further studies.
Sytl1 functions as a Rab27 effector protein in a wide variety of cells [21, 22, 23] . Genistein treatment also altered the methylation patterns of the Sytl1 promoter (Figure 4) . In contrast to the Ucp1 promoter, the decrease in methylation following genistein treatment occurred preferentially at the 223 CpG site. To study the somatic methylation pattern of the Sytl1 promoter, DNA was extracted from adult mouse liver and lung and analyzed ( Figure  S10 ). The methylation patterns characteristic of hypomethylation at CpG 223 were observed in the genistein-exposed ES cells on day 10 as well as in adult somatic tissues. Again, genistein treatment lowered the methylation level of the Sytl1 promoter, which could lead to the formation of a somatic DNA methylation pattern.
It is unclear whether the genistein-mediated differential methylation detected at the early embryonic stage in intrinsic genes (Ucp1 and Sytl1) persists until later stages of development. Our demonstration that the methylation levels changed following genistein exposure during the post gastrulation period is in accord with the idea that the genistein-mediated methylation changes in A vy are generated before germ layer differentiation. The epigenetic changes established in tissue stem cells that start to appear at the post-gastrulation period may persist until the later stages of development, or they may be modified during terminal differentiation of individual tissues. The methylation dynamics at sequential stages of development must be further clarified by spatiotemporal investigations.
We compared our genistein-mediated DMRs with the DMRs previously found in intrauterine growth retardation (IUGR) neonates [24] . There were no overlaps in the lists for top genes between genistein-mediated DMRs and IUGR DMRs. However, both types of DMRs seemed to share important similarities. First of all, the magnitude of DNA methylation changes for both types of DMRs was markedly less than many tissue-specific or cancerrelated differences. In addition, long-range changes in methylation levels did not occur over a gene locus in both DMRs. Rather, the methylation changes specifically occurred at particular sites among multiple alternative promoters in some genes. As for Ucp1 and Sytl1, they do not seem to have alternative promoters, yet the promoter methylation levels also were changed in the IUGR neonates, albeit in the opposite direction of genistein treatment (higher methylation in IUGR than in control samples) [24] . It would be interesting to investigate whether these two genes are commonly sensitive to intrauterine environmental factors.
To the best of our knowledge, this study is the first report of the effects of genistein treatment on DNA methylation patterns during ES cell differentiation. We demonstrated that genistein perturbed methylation regulation subsequent to de novo methylation, resulting in alteration of the methylation levels of a subset of promoters in an early embryonic stage. In the future, we plan to investigate how this alteration influences lifetime methylation patterns. Figure S1 Treatment with 5 mM genistein (GEN) does not impede cardiomyocyte differentiation of embryonic stem cells. Five culture conditions were tested for cardiomyocyte differentiation: no additives, dimethyl sulfoxide (DMSO) solvent only, 1 mM GEN, 5 mM GEN, and 10 mM GEN. Embryoid body (EB) formation was induced by hanging-drop culture (one drop contains 20 ml cell suspension at 4610 4 cells/ml) without leukemia inhibitory factor for two days, followed by two days of suspension culture. The EBs were transferred to a 100-mm gelatinized dish under individual culture conditions. Differentiation was determined by microscopic inspection of 20 EB outgrowths for each plate. The number of EBs containing contracting cardiomyocytes Figure 4 . The methylation levels of the Sytl1 promoter decreased following genistein (GEN) treatment. A: The genomic location and other features of the mouse Sytl1 promoter are shown. The sequence identifier containing the Sytl1 promoter covers chr4: 132534642-132536442 (NCBI36/mm8 assembly). MspI fragment-based DNA methylation typing identified the MspI fragment at chr4: 132534712-132535246 (281 to +451 relative to TSS) as a GEN-mediated differentially methylated region (DMR). The simple repeat (GAG)n is found in the region (from 251 to 224). Five probes reside in the DMR (orange rectangles); the region from 2221 to +220 (magenta rectangle) was analyzed with bisulfite sequencing. B: The mean and standard deviations for the log 2 was counted every day; GEN exposure did not inhibit cardiomyocyte differentiation up to concentrations of 5 mM. (TIF) Figure S2 Marker gene expressions during embryonic stem cell differentiation. The expression levels of differentiation marker genes were analyzed by real-time PCR assay. Regardless of genistein treatment, the decline of Pou5f1 (a pluripotency marker) and the transient elevation of T (a gastrulation marker) expression occurred, indicating that normal ES cell differentiation was proceeding. The elevated expression of ectoderm markers (Fgf5 and Wnt3a) was similarly observed both in control and genistein-treated cells on day 4. The expression of mesoderm (Pdgfra, Tbx5) and endoderm (GATA4, GATA6) markers was also similarly increased in both conditions on day 10. (TIF) Figure S3 Schematic outlines for MspI fragment-based DNA methylation typing (MFMT) assay and NimbleGen probe selection. For MFMT, probes were selected from the NimbleGen promoter array probe set. Probes carrying MspI sites present short lengths for annealing to the amplified PCR products; therefore, NimbleGen probes carrying MspI sequences were excluded from further analysis. Because the PCR products were 100-1000 bp long, probes were selected that were enclosed by two MspI sites separated by that size range. Genomic DNA was initially digested by MspI and ligated to an oligonucleotide adaptor pair. The ligated products were digested by a methylationsensitive restriction enzyme (HpaII or McrBC), and the digestionresistant fragments were amplified by PCR. If the CpG at the end of the MspI fragment was unmethylated, the adaptor- 
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